Clinic Roundup

• KAI Pharmaceuticals Inc., of South San Francisco, reported Phase II results showing that KAI-4169, its long-acting intravenous calcium sensing receptor agonist, was effective in treating secondary hyperparathyroidism in patients with chronic kidney disease, with 33 percent and 49 percent reductions in parathyroid hormone (PTH) from baseline in the 5-mg and 10-mg dose groups, respectively (p < 0.05 vs. placebo for both groups). In the 10-mg group, 76 percent of subjects achieved ≥ 30 percent reduction in PTH, and 67 percent of subjects achieved a PTH level 300 ≤ pg/mL at the end of the treatment period. Data were presented at the American Society of Nephrology's Kidney Week meeting in Philadelphia.